Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00720148 · ClinicalTrials.gov registry record · Phase 1
A Phase I Trial of Bortezomib and Sunitinib
A Phase 1 study, sponsored by Emory University.
- Completed
- Registry status
- Phase 1
- Development phase
- 30
- Enrollment target
NCT00720148 is a Phase 1 study that has completed, run by Emory University. The registered enrollment target is 30 participants.
The verdict
NCT00720148, a Phase 1 study, has completed, sponsored by Emory University.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 30 participants
- Enrollment target
Study Summary
The purpose of this study is to test the effect of the combination of sunitinib and bortezomib. We will see what effects it has on your cancer and find the highest dose of each agent that can be given without causing severe side effects.
Interventions
- DRUG Sunitinib and Bortezomib
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 30 participants |
| Start Date | 2008-02 |
| Est. Completion | 2010-07 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00720148
The ClinicalTrials.gov registry entry for NCT00720148 describes a study currently listed as completed, categorized as Phase 1. The registered enrollment target is 30 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Emory University, which has 1,208 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which Sunitinib and Bortezomib is the first listed.
NCT00720148 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00720148 about?
NCT00720148 is a clinical study titled "A Phase I Trial of Bortezomib and Sunitinib". The purpose of this study is to test the effect of the combination of sunitinib and bortezomib. We will see what effects it has on your cancer and find the highest dose of each agent that can be given without causing severe side effects.
What is the current status of trial NCT00720148?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 30 participants. The study started on 2008-02. Estimated completion is 2010-07.
What interventions are being tested in trial NCT00720148?
The interventions under investigation include: Sunitinib and Bortezomib (DRUG).
Who is sponsoring clinical trial NCT00720148?
This trial is sponsored by Emory University, which has 1,208 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.